Clinical Trial Update: NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) [Phase 1]

View source ↗

Summary

Phase 1 trial examining NY-ESO-1 protein vaccine with imiquimod as adjuvant in melanoma (adjuvant setting) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Imiquimod (imiquimod)
• NY-ESO-1 protein vaccine (NY-ESO-1 protein vaccine)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2020-10-22